A. Otsuka

Oncology · 2018

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom A. Otsuka trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. E. Wherry (in Immunology)

Papers from A. Otsuka's perspective

Ordered by how strongly the researchers A. Otsuka trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  2. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell)
  3. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
  4. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
  5. T cell exhaustion (Nature Immunology)
  6. PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
  7. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (Journal of Immunology)
  8. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (New England Journal of Medicine)
  9. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma (New England Journal of Medicine)
  10. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors (Proceedings of the National Academy of Sciences of the United States of America)

Their papers